FDA computer software assurance represents the most important modernization of validation practices for medical device manufacturers in 2025. The FDA finalized guidance recently that changes the traditional checkbox compliance approach. This new guidance promotes a risk-based methodology focused on critical thinking and appropriate validation efforts.
The guidance describes computer software assurance as an approach to build confidence in automation used for production or quality systems. Medical device production relies on computers and automated data processing systems. These recommendations enhance product quality and patient safety while leading to higher-quality outcomes. The risk posed to product quality and patient safety determines the required validation effort .
We’ll get into implementing FDA’s computer software assurance guidance to work in this piece. Our discussion covers methods to determine software’s intended use, apply risk-based approaches, choose appropriate assurance activities, and maintain proper documentation for compliance. These changes ended up benefiting quality teams by helping them focus validation efforts where they matter most.
1. Understanding the Intended Use of Software
The life-blood of FDA computer software assurance lies in figuring out if your software needs validation. Your software’s intended use forms the foundation of all validation decisions and affects how much validation you need to do.
a. What qualifies as production or quality system software
Software validated under 21 CFR 820.70(i) [1] falls into production or quality system category. FDA guidance states that software’s intended purpose, not its technical features, determines if it needs validation. You must validate software used in manufacturing, quality control, or data collection and processing for quality systems [2]. Cloud computing solutions like IaaS, PaaS, and SaaS also need validation when used for production or quality purposes [2].
General business software like email apps or infrastructure support software doesn’t usually need validation unless you use it specifically for quality system purposes [2].
b. Direct vs. supporting software roles
FDA splits software into two main categories based on intended use:
Directly used software – Programs that run production processes, inspection, testing, or collect data for production. This type also has software that runs quality system processes or keeps quality records [2].
Supporting software – Tools that test software systems, run testing activities, or handle general record-keeping outside quality records [2].
Both types need validation, but supporting software usually carries less risk. This means you can do less validation while keeping things safe [2].
c. Examples of intended use in real-life systems
A commercial off-the-shelf (COTS) spreadsheet program shows how this works. You might only need basic vendor checks and installation validation if you just log time and temperature readings in a curing process [2]. The same spreadsheet needs more validation if it uses custom formulas to calculate process performance stats because the risk goes up [2].
Cloud storage solutions work the same way. An IaaS cloud storage that holds quality records counts as directly used in quality systems. The same IaaS solution storing production data that isn’t part of quality records wouldn’t need validation [2].
Here’s the bottom line: You should look at each feature, function, and operation of your software to create risk-based assurance strategies that make sense. One-size-fits-all validation approaches don’t work.
2. Applying a Risk-Based Approach to Software Assurance
A risk-based approach is at the heart of FDA computer software assurance. Quality teams can allocate resources better by focusing on areas that affect safety and quality the most.
a. What is high process risk?
Software features or functions pose high process risk when their failure could create quality problems that compromise safety [3]. High process risk happens when software failures might increase medical device risk and harm patients [4].
Examples of high process risk functions include those that:
Maintain critical process parameters (temperature, pressure)
Measure or determine product acceptability with limited human review
Automatically adjust process parameters without human oversight
Produce instructions necessary for safe device operation [2]
b. How to assess process vs. medical device risk
Risk assessment requires clear distinction between process and medical device risks. Process risks can compromise production or quality systems. Medical device risks directly relate to potential patient harm [5].
Software failures don’t follow probability patterns. Manufacturers should evaluate reasonably foreseeable failures and what they mean [5]. Risk analysis must look at factors that could prevent software from working as intended. These include system configuration, security, data storage, and operator error [5].
c. Binary vs. spectrum-based risk classification
FDA guidance presents two classifications—”high process risk” and “not high process risk” [2]. This simple approach helps prioritize validation efforts. The FDA recognizes that process risks range from high to low on a spectrum [5].
Manufacturers can set intermediate risk levels to determine assurance activities [5]. Many organizations use detailed categories to customize their validation approach [6].
d. Examples of risk-based decisions
An Enterprise Resource Planning system that automates material ordering serves as a good example. Qualified personnel check materials before production use, which makes it an intermediate risk. Human oversight prevents safety issues [2]. Patient safety remains the key concern when software fails.
Biostrategenix stays current with guidance and regulations. Let us help you design and deploy a Part 11 compliant system by utilizing our experience in computer system software assurance.
3. Choosing the Right Assurance Activities
The FDA’s CSA guidance transforms testing approaches to prioritize value over documentation volume. Quality teams must select assurance activities based on risk assessment results.
a. Scripted vs. unscripted testing methods
i. Scripted testing validates high-risk software functions through detailed steps and expected results [7]. The process needs strong scripted testing that traces back to requirements. Mixed-risk features can use a blend of limited scripted testing approaches [7].
ii. Unscripted testing works well for not-high-risk functions without requiring step-by-step documentation [7]. Testers can rely on their expertise rather than extensive protocols.
b. Scenario testing and exploratory testing
Unscripted methods like scenario testing and exploratory testing help find hidden defects effectively. Exploratory testing finds approximately 11% more software defects than scripted approaches [8]. Complex bugs needing three or more actions to trigger show a 33% higher detection rate [8].
c. Leveraging vendor documentation and SDLC artifacts
CSA lets you use vendor documentation and software development lifecycle artifacts as valid evidence [9]. Strategic vendor evaluations and certification reviews reduce redundant validation efforts.
d. Using automated tools and logs for evidence
System logs and audit trails are better evidence options than paper documentation [10]. FDA inspectors focus on your risk classification reasoning and matching assurance activities [10].
e. When to scale assurance activities up or down
Risk assessment results should guide your testing approach. Unscripted methods work for low-risk features while critical functions need scripted testing [6]. Your assurance activities must match the identified process risk directly [3].
4. Establishing Records and Maintaining Compliance
Documentation under FDA computer software assurance emphasizes quality over quantity. The focus remains on gathering enough evidence to show that software works as intended.
a. What documentation is required under FDA CSA
Manufacturers must keep sufficient documentation for each assurance activity to prove fitness for intended use. A complete record usually has:
The software’s intended use
Risk-based analysis and classification
Summary of assurance activities (objectives, results, deviations)
Conclusion of acceptability with risk justification
Details of who did the activity and when [11]
FDA stresses that documentation should be “no more than necessary” to demonstrate assurance [11]. This marks a transformation from traditional approaches that demanded complete documentation whatever the risk level.
b. Using digital records and audit trails
Digital records are now FDA’s preferred choice over paper documentation. The agency prefers system logs, audit trails, and automated test outputs instead of screenshots or duplicate paperwork [11]. Manufacturers should use native electronic evidence that software systems generate during validation activities [12].
This method matches FDA’s wider adoption of electronic records management. Purpose-built validation automation platforms (VAPs) help streamline these activities while staying compliant [13].
c. Going together with ISO 13485 and 21 CFR Part 820
FDA’s Quality System Regulation (21 CFR Part 820) will coordinate with ISO 13485:2016 on February 2, 2026 [2]. This comprehensive approach requires manufacturers to document their software’s intended use decisions through their quality management system [2].
FDA guidance points out that QS regulation and QMSR requirements are very similar [14]. Manufacturers might find it helpful to analyze and compare their records created before February 2026 to ensure they meet QMSR requirements [14].
d. Cloud computing considerations (IaaS, PaaS, SaaS)
The guidance now defines cloud computing models (IaaS, PaaS, SaaS) and their validation expectations. To cite an instance, you might need to validate an IaaS cloud storage solution if you use it for quality records. The validation focuses on features that matter for record integrity and 21 CFR Part 11 requirements [2].
Biostrategenix stays current with guidance and regulations. Let us show you how our experience in computer system software assurance can help build and implement a Part 11 compliant system.
5. Conclusion
FDA Computer Software Assurance marks a turning point for medical device quality teams in 2025. This piece shows how this guidance changes validation from paper-heavy practices to smart, risk-based approaches. Quality teams can now focus their work where it really counts – areas that directly affect product quality and patient safety.
Teams can now use their resources better. The guidance pushes teams to think carefully about how they’ll use the software and tell the difference between direct-use and supporting software. Then validation work matches actual risk levels instead of creating extra paperwork.
CSA has substantially changed how teams handle assurance activities. They can pick between scripted testing for high-risk functions or unscripted methods when risks are lower. Teams can also use vendor documentation and development materials as valid proof, which cuts down on duplicate work.
Documentation needs have become more practical. The FDA values quality over quantity and prefers digital records and audit trails as evidence. This approach lines up perfectly with the upcoming harmonization between 21 CFR Part 820 and ISO 13485:2016.
Looking ahead, quality teams that adopt these principles will stay compliant while cutting down their validation work. The main point stays clear – validate what matters most, think critically about risks, and document enough but not too much. CSA gives teams a chance to make software validation practices both faster and more effective.
Key Takeaways
The FDA’s Computer Software Assurance guidance transforms medical device validation from checkbox compliance to strategic, risk-based approaches that prioritize patient safety and product quality.
• Focus validation on intended use: Distinguish between production/quality system software requiring validation versus general business software that typically doesn’t need extensive validation efforts.
• Apply risk-based thinking over blanket approaches: Classify software as “high process risk” when failure could compromise safety, then scale validation activities proportionally to actual risk levels.
• Choose appropriate testing methods: Use scripted testing for high-risk functions and unscripted/exploratory testing for lower-risk features to maximize defect detection while reducing documentation burden.
• Leverage digital evidence and vendor documentation: Replace paper-heavy validation with system logs, audit trails, and SDLC artifacts as preferred evidence sources.
• Document sufficiently, not excessively: Maintain records showing software fitness for intended use while eliminating unnecessary documentation that doesn’t add validation value.
This modernized approach allows quality teams to allocate resources more effectively, focusing validation efforts where they truly impact patient safety while reducing overall compliance burden. The guidance aligns with the upcoming harmonization between 21 CFR Part 820 and ISO 13485:2016, positioning forward-thinking organizations for long-term success.
References
[1] – https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software-0
[2] – https://www.fda.gov/media/188844/download
[3] – https://ispe.org/pharmaceutical-engineering/march-april-2024/computer-software-assurance-and-critical-thinking
[4] – https://www.assurx.com/an-overview-of-the-fda-draft-of-csa-guidance-for-quality-systems/
[5] – https://www.fda.gov/media/161521/download
[6] – https://www.hoganlovells.com/en/publications/fda-finalizes-computer-software-assurance-guidance-for-production-and-quality-system-software
[7] – https://www.ddismart.com/blog/fda-software-assurance-guidance-for-production-and-quality-system-software/
[8] – https://www.meddeviceonline.com/doc/reduce-risk-with-exploratory-medical-device-software-testing-0001
[9] – https://www.aurevia.com/insights/news/fda-new-guidance-transforms-software-validation-for-production-and-quality-systems
[10] – https://www.nsf.org/ie/en/life-science-regulatory-news/fda-final-guidance-on-computer-software-assurance-csa
[11] – https://gmpinsiders.com/fda-2025-guidance-csa/
[12] – https://double-helix.com/posts-aside/fda-finalizes-csa-guidance-whats-changed-why-it-matters/
[13] – https://www.fdli.org/2023/05/advancing-the-transition-to-computer-software-assurance/
[14] – https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked
Leave a Reply